PE20141183A1 - Sensibilizantes de (bacterioclorofila) para el tratamiento de enfermedades y trastornos oculares - Google Patents

Sensibilizantes de (bacterioclorofila) para el tratamiento de enfermedades y trastornos oculares

Info

Publication number
PE20141183A1
PE20141183A1 PE2014000246A PE2014000246A PE20141183A1 PE 20141183 A1 PE20141183 A1 PE 20141183A1 PE 2014000246 A PE2014000246 A PE 2014000246A PE 2014000246 A PE2014000246 A PE 2014000246A PE 20141183 A1 PE20141183 A1 PE 20141183A1
Authority
PE
Peru
Prior art keywords
bacteriochlorophyl
treatment
sensitizers
disorders
compounds
Prior art date
Application number
PE2014000246A
Other languages
English (en)
Spanish (es)
Inventor
Avigdor Scherz
Yoram Salomon
Arie Marcovich
Alexander Brandis
Daniel Wagner
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of PE20141183A1 publication Critical patent/PE20141183A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2014000246A 2011-08-23 2012-08-23 Sensibilizantes de (bacterioclorofila) para el tratamiento de enfermedades y trastornos oculares PE20141183A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161526414P 2011-08-23 2011-08-23

Publications (1)

Publication Number Publication Date
PE20141183A1 true PE20141183A1 (es) 2014-10-05

Family

ID=46889394

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000246A PE20141183A1 (es) 2011-08-23 2012-08-23 Sensibilizantes de (bacterioclorofila) para el tratamiento de enfermedades y trastornos oculares

Country Status (20)

Country Link
US (4) US9452172B2 (enExample)
EP (1) EP2747763B1 (enExample)
JP (1) JP6215203B2 (enExample)
KR (1) KR101962991B1 (enExample)
CN (1) CN103930108B (enExample)
AU (1) AU2012298156B2 (enExample)
BR (1) BR112014004306A2 (enExample)
CA (1) CA2846011C (enExample)
CL (1) CL2014000432A1 (enExample)
DK (1) DK2747763T3 (enExample)
ES (1) ES2856698T3 (enExample)
HK (1) HK1199412A1 (enExample)
HU (1) HUE053321T2 (enExample)
IN (1) IN2014CN02153A (enExample)
MX (1) MX360683B (enExample)
PE (1) PE20141183A1 (enExample)
PT (1) PT2747763T (enExample)
RU (1) RU2632439C2 (enExample)
WO (1) WO2013027222A1 (enExample)
ZA (1) ZA201402056B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP4420725A3 (en) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
WO2017015471A1 (en) 2015-07-21 2017-01-26 Avedro, Inc. Systems and methods for treaments of an eye with a photosensitizer
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
CN105601638B (zh) * 2016-01-28 2018-10-26 东北林业大学 一种叶绿酸衍生物及其制备方法、作为光敏抑菌剂及光敏杀虫剂的应用
US10342697B2 (en) 2016-04-13 2019-07-09 Avedro, Inc. Systems and methods for delivering drugs to an eye
EP4335419A3 (en) * 2016-05-05 2024-04-03 David Muller Corneal implant systems and methods
US10849855B2 (en) * 2017-01-03 2020-12-01 Vitrean, Inc. Methods and devices for treating a retinal detachment
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
CN109091685A (zh) * 2018-08-10 2018-12-28 北京市眼科研究所 一种对角膜炎提取细菌病原体的灭活方法
KR20210093901A (ko) * 2018-10-24 2021-07-28 캘리포니아 인스티튜트 오브 테크놀로지 일중항 산소를 사용한 근시 및 기타 안구 질환의 치료
US11702546B2 (en) 2018-10-24 2023-07-18 California Institute Of Technology Near-infrared heptamethine dyes for generation of singlet oxygen
WO2020117974A1 (en) * 2018-12-04 2020-06-11 Avedro, Inc. Compounds and compositions for eye treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102645A (en) 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
RU2201219C2 (ru) * 2001-04-24 2003-03-27 Макаров Константин Алексеевич Фармакологическая композиция пролонгированного действия
US20040266748A1 (en) * 2001-10-03 2004-12-30 Robinson Byron C Photosensitizing carbamate derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
EP1753457B8 (en) * 2004-06-07 2016-09-21 Yeda Research And Development Co., Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
KR101502632B1 (ko) 2006-10-24 2015-03-17 캘리포니아 인스티튜트 오브 테크놀로지 신체 조직의 물리적 및/또는 화학적 성질에 영향을 주는 광화학적 요법
RU2404768C1 (ru) * 2009-10-28 2010-11-27 Федеральное агентство по науке и инновациям Глазные капли
JPWO2011099602A1 (ja) * 2010-02-12 2013-06-17 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用

Also Published As

Publication number Publication date
DK2747763T3 (da) 2021-03-29
ZA201402056B (en) 2015-11-25
BR112014004306A2 (pt) 2017-03-28
JP6215203B2 (ja) 2017-10-18
US20190231874A1 (en) 2019-08-01
US20140378888A1 (en) 2014-12-25
CN103930108B (zh) 2017-05-24
CL2014000432A1 (es) 2014-11-28
RU2632439C2 (ru) 2017-10-04
MX2014002107A (es) 2015-04-16
US20160354468A1 (en) 2016-12-08
AU2012298156A1 (en) 2014-04-10
EP2747763B1 (en) 2020-12-30
HUE053321T2 (hu) 2021-06-28
PT2747763T (pt) 2021-02-22
IN2014CN02153A (enExample) 2015-05-29
KR20140088514A (ko) 2014-07-10
CN103930108A (zh) 2014-07-16
US9452172B2 (en) 2016-09-27
ES2856698T3 (es) 2021-09-28
MX360683B (es) 2018-11-13
HK1199412A1 (en) 2015-07-03
JP2014524465A (ja) 2014-09-22
WO2013027222A1 (en) 2013-02-28
US11058772B2 (en) 2021-07-13
KR101962991B1 (ko) 2019-03-27
EP2747763A1 (en) 2014-07-02
CA2846011A1 (en) 2013-02-28
CA2846011C (en) 2019-10-15
US20210330792A1 (en) 2021-10-28
AU2012298156B2 (en) 2017-08-17
RU2014110784A (ru) 2015-09-27

Similar Documents

Publication Publication Date Title
AR095371A1 (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos
PE20151559A1 (es) Nuevos derivados de piridina
EA201991316A1 (ru) Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту
EA201590092A1 (ru) АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ
NI201300068A (es) Moduladores del receptor de glucagón
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
AR101177A1 (es) Inhibidores de la syk
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
ECSP14013211A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20141997A1 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
PE20170323A1 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble

Legal Events

Date Code Title Description
FC Refusal